Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
136 hedge funds and large institutions have $188M invested in Kezar Life Sciences in 2023 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 51 increasing their positions, 39 reducing their positions, and 17 closing their positions.
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
31% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 39
23% more call options, than puts
Call options by funds: $2.91M | Put options by funds: $2.36M
11% more funds holding
Funds holding: 123 → 136 (+13)
0.09% more ownership
Funds ownership: 8.4% → 8.48% (+0.09%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
53% less capital invested
Capital invested by funds: $401M → $188M (-$213M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$19.6M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$8.36M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.42M |
| 4 |
O
OrbiMed
New York
|
+$5.08M |
| 5 |
Barclays
London,
United Kingdom
|
+$3.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$17.5M |
| 2 |
DM
Deerfield Management
New York
|
-$10.1M |
| 3 |
CA
CHI Advisors
New York
|
-$6.94M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.87M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$4.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DU
151
Delphia (USA)
Toronto,
Ontario, Canada
| – | -$71.4K | -1,014 | Closed |
|
152
Allspring Global Investments
Charlotte,
North Carolina
| – | -$15.8K | -224 | Closed |
|
|
FGAM
153
Financial Gravity Asset Management
Lakeway,
Texas
| – | -$129 | -1 | Closed |
|
154
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$694 | +12 | New |
|
KZR Hedge Fund Activity: Q1 2023 in Review
136 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q1 2023, worth a combined $188M — down 53% from $401M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new KZR positions and 17 closed out — a net gain of 13 holders — while 51 added to existing stakes and 39 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $19.6M. The largest seller was Bellevue Group, cutting an estimated $17.5M.
- 136 institutional investors held Kezar Life Sciences (KZR) as of Q1 2023, up from 123 in Q4 2022.
- Funds reported $188M of Kezar Life Sciences stock for Q1 2023, down 53% quarter-over-quarter.
- 30 funds opened new Kezar Life Sciences positions in Q1 2023 and 17 closed out, a net change of +13 holders.
- The largest Kezar Life Sciences buyer in Q1 2023 was Suvretta Capital Management, an estimated $19.6M added.
- The largest Kezar Life Sciences seller in Q1 2023 was Bellevue Group, an estimated $17.5M sold.
Based on aggregated 13F filings for Q1 2023.